The bosutinib structural isomer differs from bosutinib itself only in the positions of the chlorine and methoxy substituents on the aniline ring. Bosutinib is an anticancer chemotherapeutic compound that inhibits src and Abl kinases and is clinically used to treat chronic myeloid leukemia. In vivo, bosutinib does not induce apoptosis but does decrease cell proliferation, inhibit cell differentiation, and inhibit tumor metastases, all likely through inhibition of downstream MAPK signaling. Additionally, bosutinib may alter IGF-1 and IGF binding protein 3 (IGF bp3) signaling as well. This compound also shows neuroprotective and cognition enhancing benefits in animal models of Alzheimer’s disease. Bosutinib clears β-amyloid plaques and increases cognitive function by facilitation interaction between parkin and Beclin-1 proteins, which then accumulate in the lysosome for degradation.